Doreen Wiggins, MD, FACOG, FACS, is an affiliated physician at the Women’s Medicine Collaborative. She is director of the Cancer Survivorship Medicine Program, and is a clinical assistant professor of surgery, and clinical assistant professor of obstetrics and gynecology at The Warren Alpert Medical School of Brown University. She received her undergraduate degree from the University of Rhode Island and her medical degree from The Warren Alpert Medical School of Brown University. She pursued further medical training at Women & Infants Hospital and completed a Society for Surgical Oncology Breast Disease fellowship, and an intensive course in cancer risk assessment at the City of Hope in Los Angeles, California. Wiggins is a fellow of both the American College of Obstetricians and Gynecologists and the American College of Surgeons. She is the founder of the Center for Obstetrics & Gynecology in Providence. Her areas of expertise are breast cancer surgery, gynecologic surgery, female cancer genetics, female sexuality and cancer survivorship.
|
Amy Pilotte, MSN, ANP-BC, is a nurse practitioner in the Women’s Cancer Survivorship Medicine Program at the Women’s Medicine Collaborative. She received an undergraduate degree in health care administration at Stonehill College in Easton, Massachusetts, and her master of science degree in nursing at the Massachusetts General Hospital Institute of Health Professions in Boston. She is currently working toward her certification in palliative care.
Her past clinical experience includes her role as a nurse practitioner in the Sarcoma Center at the Dana-Farber Cancer Institute in Boston. In addition to direct patient care, in collaboration with comprehensive care teams, a large focus of Amy’s role was on patient education, palliative care, pain management, emotional support and cancer survivorship.
Pilotte is a board certified adult nurse practitioner and is certified by the American Nurses Credentialing Center. Her clinical and research interests include cancer management, side effects, optimizing safety, and the patient’s experience in clinical trials.
|